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1LETTER TO THE EDITOR
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grover’s Disease
fter Bone Marrow
ransplantation
Skin rashes after allogeneic bone marrow transplan-
ation (BMT) are not uncommon, and etiologies include
raft-versus-host disease (GVHD), drug rashes, infec-
ions, etc. [1]. In this regard, transient acantholytic
ermatosis or Grover’s disease has been uncommonly
ssociated to oncologic patients [2] and rarely after
llogeneic BMT [1,3]. After a ﬁrst patient with Grov-
r’s disease [4] was seen in consultation for suspected
VHD, we reviewed the records of 236 patients re-
erred to the GVHD consultation service since Octo-
er 2003, and found 3 other patients with Grover’s
isease and no GVHD.
The ﬁrst patient was a 48-year-old white male,
iagnosed with chronic lymphocytic leukemia. The
atient progressed after several therapies, so he pro-
eeded with a haploidentical nonmyeloablative BMT
fter total body irradiation (TBI), ﬂudarabine and cy-
lophosphamide, and cyclophosphamide, tacrolimus,
nd mycophenolate mofetil (MMF) for GVHD pro-
hylaxis [5]. By day 50 post-BMT, he developed a
eneralized pruritic rash with no gastrointestinal or
iver abnormalities. A skin biopsy was obtained and he
as started on immunosuppression for presumed
VHD. The biopsy had epidermal acantholysis oc-
urring at multiple levels above the basal layer and no
VHD (Figure 1). Immunosuppression was discon-
inued and the rash resolved.
The second patient was a 58-year-old gentleman
ith a plasma cell leukemia, who was 37 days post-
onmyeloablative allogeneic BMT, and had re-
eived cyclophosphamide and MMF for GVHD
rophylaxis. Chimerism studies obtained by restric-
ion fragment length polymorphism (RFLP) 7 days
arlier showed a mixed chimerism (66%-80% donor
n peripheral blood). He presented with an exten-
ive skin rash compatible with GVHD that when
iopsied indicated Grover’s disease (similar to the
ne in Figure 2). He did not have gastrointestinal or
iver abnormalities.
The third patient was a 62-year-old white gentle-
an with myelodysplastic syndrome (MDS), who un-
erwent a nonmyeloablative haploidentical BMT.
orty-nine days posttransplant he developed a gener-
lized rash that showed skin GVHD, and was treated s
116ith steroids, to which he responded promptly.
inety days after BMT, he developed a new rash that
as biopsied and it indicated Grover’s disease. Thirty
ays earlier he was a full chimera on peripheral blood
y RFLP. He did not have gastrointestinal or liver
bnormalities.
The last patient was a 64-year-old gentleman who
as admitted for his second cycle of R-EPOCH. He
ad received an allogeneic transplant 2 years earlier
ut relapsed. He developed a skin rash on day 2 of
hemotherapy that was biopsied and indicated Grov-
r’s disease. His chimerism studies obtained 1 month
efore showed mixed chimerism (92% donor on pe-
ipheral blood by RFLP). He also did not have gas-
rointestinal or liver abnormalities.
To our knowledge, this is the largest series of
atients with Grover’s disease after allogeneic trans-
lant that has ever been reported. This self-limited
rocess has been associated with heat and excessive
igure 1. A, Features typical of Grover’s disease including dysker-
tosis (short arrow), acantholysis (long arrows), and elongation of
ete ridges are apparent in the biopsy (H&E 200). B, In contrast,
cute GVHD is histologically characterized by subtle interface inﬂam-
ation, vacuolization of basal keratinocytes, and associated dyskerato-
is. The overlying epidermis is of normal thickness, has minimal spon-
iosis, and an unremarkable corniﬁed layer (H&E 200).weating. In the past, there has been discussion about
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Letter to the Editor 1117he need of obtaining biopsies in patients with skin
ashes post-BMT [6]. The biopsy should be a part of
he diagnostic workup of these patients, and the result
f this biopsy should be considered when a diagnosis is
ade. A negative biopsy does not negate GVHD.
owever, when the biopsy is positive for another
ntity different from GVHD, as in these cases, assum-
ng it is GVHD and treating it as such is problematic.
ithout a biopsy, these patients would have received
ggressive immunosuppression for a prolonged period
f time. As Grover’s disease is a self-limited condition,
he use of immunosuppressants is not warranted, and
an be deleterious in these patients. The relevance of
his letter is to alert clinicians to another diagnosis in
atients with rashes post-BMT, as not every rash in
igure 2. Typical appearance of Grover’s disease showing edema-
ous papules with excoriation. This is indistinguishable from a rash
nduced by GVHD.his setting is GVHD. dEFERENCES
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